The Lancet: July 18, 2013
The Lancet in conversation with - Un pódcast de The Lancet Group - Viernes
Categorías:
Richard Gelber discusses results of the HERA trial comparing 2 years vs 1 year trastuzumab for HER2 positive breast cancer.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
